RE: Market Musings Podcast by StockBox21 Dec 2023 11:51
Ice, I know, everyone knows, the platform works, that was known at the end cohort one.
Its about Efficacy. The safety and tolerability was simply the very most basic hurdle that any knew treatment has to clear.
What if this extends life by 6-12 months but what if it makes little difference to quality of life. (yes the side effects could be vastly reduced), but if the person, remains bed ridden, or opens itself to perhaps further surgery and more hospitalisation, then will the cost to the end user (the funder of the treatment) be acceptable?
I am not saying any of this will come to pass but its this knee jerk "its going to be fantastic on what we already know", assumption that to me there is simply no where near enough evidence to justify these claims.
So far but and so good. But where is the detailed data of the tumour shrinkage? And why only one patient? What are the side effects? How much variation is there on side effects between patients so far?
Does any of this matter at this stage of the trial?
Its all about now, the next hurdle. This is the one, the efficacy, that will prove how well it works, and from there maybe, just maybe, some sort of valuation will be possible.
To me all we have done is a built a new engine for a car. We have just filled the petrol tank, because without the fuel its not going anywhere, then the next step was to push the start button and see if it fires up. So far so good, now its time to put it on track and see how well it goes. (If it doesn't perform , the success of the first 2 steps don't really matter do they?)